NRx Pharmaceuticals (NASDAQ:NRXP) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has a $34.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Ascendiant Capital Markets reissued a “buy” rating and set a $48.00 price objective (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. HC Wainwright upped their target price on NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Finally, BTIG Research reiterated a “buy” rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, NRx Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $38.00.

NRx Pharmaceuticals Price Performance

NRXP stock opened at $2.13 on Tuesday. The business has a 50-day moving average price of $1.94 and a 200 day moving average price of $2.44. The company has a market capitalization of $67.88 million, a P/E ratio of -1.53 and a beta of 1.97. NRx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Monday, March 23rd. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.28. The business had revenue of $0.98 million for the quarter, compared to the consensus estimate of $7.53 million. On average, analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NRXP. Anson Funds Management LP lifted its position in NRx Pharmaceuticals by 26.2% during the third quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock valued at $6,683,000 after acquiring an additional 420,129 shares during the last quarter. AdvisorShares Investments LLC grew its holdings in NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after purchasing an additional 78,339 shares during the last quarter. One Wealth Management Investment & Advisory Services LLC increased its position in shares of NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares in the last quarter. Ethos Financial Group LLC acquired a new position in shares of NRx Pharmaceuticals during the third quarter worth $39,000. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at $994,000. Institutional investors own 4.27% of the company’s stock.

Trending Headlines about NRx Pharmaceuticals

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” and set a $34.00 price target — a very large upside projection that can attract momentum buyers. Benzinga Article
• Positive Sentiment: BTIG Research reaffirmed its “buy” and set a $25.00 price target, another high-profile bullish endorsement likely supporting the rally. Benzinga Article
• Positive Sentiment: Q4 EPS of $0.19 topped consensus (loss of $0.09), a clear earnings beat that likely improved sentiment despite underlying revenue weakness. Press Release
• Neutral Sentiment: Company reported full-year 2025 results and says it ended the year with $7.8M cash and expects adequate resources to operate through 2026 given current revenue and ATM trends — supportive for near-term runway but not a long-term funding solution. GlobeNewswire Release
• Neutral Sentiment: Investor/analyst call prepared remarks/transcript available for review — useful for assessing management tone and guidance but not an immediate directional catalyst by itself. Seeking Alpha Transcript
• Negative Sentiment: Revenue for the quarter was $0.98M, well below analyst expectations (~$7.5M), which is a meaningful operational miss that could concern fundamental investors if not explained by one-time items. Zacks Article
• Neutral Sentiment: Several short-interest notices show anomalous/zero reported short positions (and NaN changes) for March — the data appears inconsistent/placeholder and does not provide a clear short-squeeze signal at this time.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.